A Phase 1 interventional study of TRTP-101 in Atrophic Scar, sponsored by CellinCells. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by CellinCells · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Cicatrix with a site in Korea, Republic of — 4 open to participants now, 5 under way, none of them phase 3. Cicatrix · Korea, Republic of.
Among the 20 studies in Cicatrix with a site in Korea, Republic of, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 15th registered.
616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.
Browse Cicatrix studies →4 of the 20 studies in Cicatrix with a site in Korea, Republic of are open now. Recruiting first, the newest first:
CellinCells · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
CellinCells · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
CellinCells · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
CellinCells · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2023.
This study's enrollment of 3 is below the median of 40 across 515 interventional studies indexed under Cicatrix.
Median enrollment 28 across the 16 interventional studies, 30 across the 4 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
CellinCells is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
CellinCells has 6 studies filed under Cicatrix — fewer than ten, so there is no comparison to draw.
2 of the studies in Cicatrix with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07950475CellinCellsMethodological Validation of Antera 3D for Quantitative Assessment of Atrophic Scars | 2027-02-26 |
| NCT07945106CellinCellsDevelopment of an ASRS-Based Photoguide for a Clinical Trial of TRTP-101 in Adults With Atrophic Scars | 2027-02-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Cicatrix with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.
A phase 1 clinical trial to evaluate dose-limiting toxicity by administering a singe dose of TRTP-101 to each of the four sites of atrophic scar.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Micro-Block (MiB) manufactured from autologous Adipose-derived Mesenchymal Stem Cells
Biological: TRTP-101
Intradermal injection of the each of four sites
Number of Participants with Dose Limiting Toxicity
Dose Limiting Toxicity is defined as Grade ≥ 3 adverse drug reaction according to CTCAE criteria for 4 weeks after administration of TRTP-101
Time frame: within 4 weeks
Mean percent change in atrophic scar volume
The depressed volume of atropic scar is measured at baseline and post-treatment visits
Time frame: 1, 4, 8 and 12 weeks
Plan to share: No
Ran from Dec 2023 to primary completion in Dec 2024, 12 months.
Of 16 phase 1 interventional studies under Cicatrix, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 17. This study's 12 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CellinCells